HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report.

AuthorsM Benucci, Gobbi F Li, A Del Rosso, M Manfredi
JournalClinical and experimental rheumatology (Clin Exp Rheumatol) 2005 Sep-Oct Vol. 23 Issue 5 Pg. 733 ISSN: 0392-856X [Print] Italy
PMID16173267 (Publication Type: Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab
Topics
  • Adalimumab
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents (therapeutic use)
  • Female
  • Humans
  • Middle Aged
  • Still's Disease, Adult-Onset (drug therapy)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: